Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo

Viral Immunology

Volumn 19, Issue 4, 2006, Pages 690-701

  Buffa, Viviana ^a,b   Negri, Donatella R M ^a   Leone, Pasqualina ^a   Borghi, Martina ^a   Bona, Roberta ^a   Michelini, Zuleika ^a   Compagnoni, Daniela ^a   Sgadari, Cecilia ^a   Ensoli, Barbara ^a   Cara, Andrea ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; GAG PROTEIN; GAMMA INTERFERON; LENTIVIRUS VECTOR;

ADOLESCENT; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MACACA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS REPLICATION;

MACACA; MACACA FASCICULARIS; MAMMALIA; MUS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33846069312     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.690     Document Type: Article

References (60)

1. Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, and Yamaguchi K: Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther 2000;7:2113-2121.
2. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, and Robinson HL: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
3. Anson DS: The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2004;2:9.
4. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, and Ruprecht RM: Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999;5:194-203.
5. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, and Letvin NL: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-492.
6. Besnier C, Takeuchi Y, and Towers G: Restriction of lentivirus in monkeys. Proc Natl Acad Sci USA 2002;99:11920-11925.
7. Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C, van der Bruggen P, and Thielemans K: Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003;5:654-667.
8. JR-FL gp120 generates durable immune responses in mice. J Gen Virol 2006;87:1625-1634.
9. Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, Davies ME, Freed DC, Hurni W, Aste-Amezaga JM, Guan L, Long R, Huang L, Harris V, Nawrocki DK, Mach H, Troutman RD, Isopi LA, Murthy KK, Rice K, Wilson KA, Volkin DB, Emini EA, and Shiver JW: Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:7663-7668.
10. Chang LJ, Urlacher V, Iwakuma T, Cui Y, and Zucali J: Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther 1999;6:715-728.
11. Connolly JB: Lentiviruses in gene therapy clinical research. Gene Ther 2002;9:1730-1734.
12. Connolly JB: Conditionally replicating viruses in cancer therapy. Gene Ther 2003;10:712-715.
13. Crameri A, Whitehorn EA, Tate E, and Stemmer WP: Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat Biotechnol 1996;14:315-319.
14. Cui Y, Iwakuma T, and Chang LJ: Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J Virol 1999;73:6171-6176.
15. Dullaers M, and Thielemans K: From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J Gene Med 2006;8:3-17.
16. + T cell responses. J Clin Invest 2003;111:1673-1681.
17. Gao F, Li Y, Decker JM, Peyerl FW, Bibollet-Ruche F, Rodenburg CM, Chen Y, Shaw DR, Allen S, Musonda R, Shaw GM, Zajac AJ, Letvin N, and Hahn BH: Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: In vitro expression and immune responses in DNA-vaccinated mice. AIDS Res Hum Retroviruses 2003;19:817-823.
18. + T cell response to the HIV-Env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-γ. Virus Res 2004;105:11-22.
19. He Y, Zhang J, Mi Z, Robbins P, and Falo LD Jr: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005;174:3808-3817.
20. Hegde R, Liu Z, Mackay G, Smith M, Chebloune Y, Narayan O, and Singh DK: Antigen expression kinetics and immune responses of mice immunized with noninfectious simian-human immunodeficiency virus DNA. J Virol . 2005;79:14688-14697.
21. Higgins JR, Sutjipto S, Marx PA, and Pedersen NC: Shared antigenic epitopes of the major core proteins of human and simian immunodeficiency virus isolates. J Med Primatol 1992;5:265-269.
22. Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, and Chameau P: A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 2006;8:265-274.
23. Irwin MJ, Laube LS, Lee V, Austin M, Chada S, Anderson CG, Townsend K, Jolly DJ, and Warner JF: Direct injection of a recombinant retroviral vector induces human immunodeficency virus-specific immune responses in mice and nonhuman primates. J Virol 1994;68:5036-5044.
24. Iwakuma T, Cui Y, and Chang LJ: Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999;261:120-132.
25. Kafri T, Blomer U, Peterson DA, Gage FH, and Verma IM: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997;17: 314-317.
26. Kamantigue E, Edwards W, Chada S, Brumm D, Austin M, Irwin M, Mento S, Kowal K, and Sajjadi N: Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly. Gene Ther 1996;3:128-136.
27. Kaufmann SH, and McMichael AJ: Annulling a dangerous liaison: Vaccination strategies against AIDS and tuberculosis. Nat Med 2005;11:S33-S44.
28. Kim JH, Majumder N, Lin H, Watkins S, and Falo LD Jr, and You Z: Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther 2005;16:1255-1266.
29. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, and Desrosiers RC: HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006;7:19-23.
30. Laube LS, Burrascano M, Dejesus CE, Howard BD, Johnson MA, Lee WT, Lynn AE, Peters G, Ronlov GS, Townsend KS, Eason RL, Jolly DJ, Merchant B, and Warner JF: Cytotoxic T lymphocytes and antibody responses generated in rhesus monkeys immunized with retroviral vector-trasduced fibroblasts expressing human immunodeficency virus type-1 IIIB ENV/REV proteins. Hum Gene Ther 1994;5:853-862.
31. Lever AM, Strappe PM, and Zhao J: Lentiviral vectors. J Biomed. Sci 2004;11:439-449.
32. Lopes L, Fletcher K, Ikeda Y, and Collins M: Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol Immunother 2005;26:1-6.
33. Mata M, and Paterson Y: Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J Immunol 1999;163:1449-1456.
34. McIver SR, Lee CS, Lee JM, Green SH, Sands MS, Snider BJ, and Goldberg MP: Lentiviral transduction of murine oligodendrocytes in vivo. J Neurosci Res 2005;82:397-403.
35. Mehlhop E, Villamide LA, Frank I, Gettie A, Santisteban C, Messmer D, Ignatius R, Lifson JD, and Pope M: Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV-specific T cell responses. J Immunol Methods 2002;260:219-234.
36. Metharom P, Ellem KA, and Wei MQ: Gene transfer to dendritic cells induced a protective immunity against melanoma. Cell Mol Immunol 2005;2:281-288.
37. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi LS, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C, von Kalle C, and Naldini L: Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-696.
38. Munk C, Brandt SM, Lucero G, and Landau NR: A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci USA 2002;99:13843-13848.
39. Nagata T, Uchijima M, Yoshida A, Kawashima M, and Koide Y: Optimization effect on translational efficiency of DNA vaccine in mammalian cells: Analysis of plasmid DNA encoding a CTL epitope derived from microorganisms. Biochem Biophys Res Commun 1999;261:445-451.
40. Nakaya Y, Nakaya T, Park M, Cros J, Imanishi J, Palese P, and Garcia-Sastre A: Induction of cellular immune responses to simian immunodeficiency virus Gag by two recombinant negative-strand RNA virus vectors. J Virol 2004;78:9366-9375.
41. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, and Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
42. Negri DR, Baroncelli S, Catone S, Comini A, Michelini Z, Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Mancini MG, Farcomeni S, Fagrouch Z, Ciccozzi M, Boros S, Liljestrom P, Norley S, Heeney J, and Titti F: Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 2004;5:1191-1201.
43. Negri DR, Buffa V, Leone P, Bona R, Borghi M, Carlini F, De Angelis F, Indraccolo S, Ensoli B, and Cara A: Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. J Immunol Methods 2004;291:153-163.
44. Neumann J, Stitz J, Konig R, Seibold E, Norley S, Flory E, and Cichutek K: Retroviral vectors for vaccine development: Induction of HIV-1-specific humoral and cellular immune responses in rhesus macaques using a novel MLV(HIV-1) pseudotype vector. J Biotechnol 2006;124: 615-625.
45. Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, and Collins MK: Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 2004;172:1582-1587.
46. Ramakrishna L, Anand KK, Mohankumar KM, and Ranga U: Codon optimization of the Tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 2004;78:9174-9189.
47. Roberts DM, Nanda A, Havenga MJE, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AAC, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, and Barouch DH: Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006;441:239-243.
48. Romano G, Claudio PP, Tonini T, and Giordano A: Human immunodeficiency virus type 1 (HIV-1) derived vectors: Safety considerations and controversy over therapeutic applications. Eur J Dermatol 2003;13:424-429.
49. Schnell T, Foley P, Wirth M, Munch J, and Uberla K: Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 2000;11:439-447.
50. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, and Emini EA: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335.
51. Someya K, Xin KQ, Matsuo K, Okuda K, Yamamoto N, and Honda M: A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 2004;78: 9842-9853.
52. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, and Sodroski J: The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 2004;427:848-853.
53. Vanniasinkam T, and Ertl HC: Adenoviral gene delivery for HIV-1 vaccination. Curr Gene Ther 2005;5:203-212.
54. Warner JF, Anderson CG, Laube L, Jolly DJ, Townsend K, Chada S, and St Louis D: Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res Hum Retroviruses 1991;7:645-655.
55. Weiss R, Teich N, Varmus H, and Coffin J: Molecular biology of tumor viruses. In Weiss R, Teich N, Varmus H, and Coffin J, eds. RNA Tumor Viruses, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982.
56. Whitney JB, and Ruprecht RM: Live attenuated HIV vaccines: Pitfalls and prospects. Curr Opin Infect Dis 2004;17:17-26.
57. Wiznerowicz M, and Trono D: Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol 2005;23:42-47.
58. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, and Chen IS: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.
59. Zolotukhin S, Potter M, Hauswirth WW, Guy J, and Muzyczka N: A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996;70:4646-4654.
60. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, and Trono D: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72:9873-9880.